# A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug

Study · id `cardio:ct-nct01888445` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01888445](<https://clinicaltrials.gov/study/NCT01888445>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01888445

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

## Technical summary

Registry record NCT01888445. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-28 (actual); primary completion 2014-09-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 130 participants (enrolled count; ClinicalTrials.gov record NCT01888445, source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)
- Started: 2013-03-28 (actual) (ClinicalTrials.gov record NCT01888445, source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)
- Primary completion: 2014-09-15 (actual) (ClinicalTrials.gov record NCT01888445, source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)
- Completion: 2014-09-15 (actual) (ClinicalTrials.gov record NCT01888445, source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01888445, source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01888445-2024-10-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug
- Condition: Renal Anemia Associated With Chronic Renal Failure (CRF)
- Intervention (Drug): roxadustat
- Intervention (Drug): darbepoetin alfa
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 696a6e2e5518e522470294ef37437f6d9cbdb804bb9a58a87b9eb934a0ca447d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
